CÉLULAS CAR-T NO TRATAMENTO DO MIELOMA MÚLTIPLO: Recentes avanços e prospectivas

• DOI: https://doi.org/10.22533/at.ed.3122409093

• Palavras-chave: Células CAR-T; Terapia; Mieloma múltiplo; Linfócitos T; BCMA

• Keywords: CAR-T cells; Therapy; Multiple myeloma; T lymphocytes; BCMA

• Abstract: CAR-T cell immunotherapy (Chimeric Antigen Receptor T cells) has proven to be a revolutionary approach in the treatment of refractory multiple myeloma. Therapies targeting B cell maturation antigen (BCMA) have shown high efficacy, even in high-risk situations. In this context, several BCMA-focused CAR-T therapies are currently under clinical development, and their clinical approval is imminent. The research was based on a time frame from 2019 to 2023, focusing on English-language studies that addressed both traditional and pioneering approaches using CAR-T cells in the treatment of multiple myeloma. Thus, this literature review utilized well-recognized health science books, as well as platforms like the Scientific Electronic Library Online (SciELO) and PubMed, as the foundation for all the scientific articles used in this research. Therefore, the major perception is that recent years have been marked by advances in research on chimeric cell therapy for the treatment of multiple myeloma, due to factors such as legal approvals and discoveries of effective mechanisms of action, which have already shown an impact on the therapeutic options available for multiple myeloma.